UK markets closed

Genmab A/S (GMAB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
33.50-0.89 (-2.59%)
At close: 04:00PM EST
34.00 +0.50 (+1.49%)
After hours: 05:35PM EST
Full screen
Trade prices are not sourced from all markets
Previous close34.39
Open34.16
Bid29.80 x 1100
Ask34.00 x 1100
Day's range33.35 - 34.33
52-week range30.10 - 49.07
Volume441,598
Avg. volume461,888
Market cap22.208B
Beta (5Y monthly)0.68
PE ratio (TTM)50.69
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    Genmab and Synaffix Enter into License Agreement for ADC Technology

    Media Release Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologiesGenmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and commercialization of resulting therapiesSynaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus tiered single digit royalties on sales of successfully commercialized therapies COPENHAGEN, Denmark and AMSTERD

  • Globe Newswire

    Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

    Company Announcement COPENHAGEN, Denmark; January 4, 2022 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading

  • Globe Newswire

    Genmab to Present at the 40th Annual J.P. Morgan Healthcare Conference

    Media ReleaseCOPENHAGEN, Denmark; January 3, 2022Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 40th Annual J.P. Morgan Healthcare Conference at 9:00 AM EST / 3.00 PM CET on January 12, 2022. The live and archived webcast of the presentation will be available on Genmab’s website at https://ir.genmab.com/events-and-presentations#content. About Genmab Genmab is an international biotechnology company with a core purpose to impr